Dopo l'orario di chiusura: 4.4018 -0.0382 -0.86%

Summit Therapeutics Inc (SMMT)

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

Summit Therapeutics Inc (SMMT)

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

A company insider recently bought 54321 shares of Summit Therapeutics Inc [SMMT]. Should You Buy? – Knox Daily - Knox Daily

Summit Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Financial Snapshot: Analyzing Summit Therapeutics Inc (SMMT)'s Key Ratio Metrics – DWinneX - The Dwinnex

A significant driver of top-line growth: Summit Therapeutics Inc (SMMT) – Sete News - SETE News

Understanding the Risks of Investing in Summit Therapeutics Inc (SMMT) – Knox Daily - Knox Daily

Zurcher Kantonalbank Zurich Cantonalbank Acquires 14098 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Citigroup - Defense World

Summit Therapeutics (NASDAQ:SMMT) Sets New 1-Year High at $5.39 - MarketBeat

Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide (NASDAQ:SMMT) - Seeking Alpha

Federated Hermes Inc. Reduces Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Federated Hermes Inc. Reduces Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Summit Therapeutics (NASDAQ:SMMT) Shares Up 8.7% - MarketBeat

Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Citigroup - MarketBeat

Summit spikes as Citi launches at Buy on lead asset - MSN

Summit spikes as Citi launches at Buy on lead asset (NASDAQ:SMMT) - Seeking Alpha

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer - citybiz

Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Citigroup - MarketBeat

Summit Therapeutics' Ivonescimab: Strong Buy; Dual-Action Approach To Cancer (NASDAQ:SMMT) - Seeking Alpha

Summit Therapeutics' Ivonescimab: Strong Buy; Dual-Action Approach To Cancer (NASDAQ:SMMT) - Seeking Alpha

SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors - MSN

Insiders Of Summit Therapeutics Reap Rewards After Their Investment Jumps Another US$8.3m - Simply Wall St

Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial Health - GuruFocus.com

Earnings call: Summit Therapeutics reports on ivonescimab trials - Investing.com India

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6% - MarketBeat

Summit Therapeutics Inc (SMMT) looking to reclaim success with recent performance – Sete News - SETE News

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 ... - wallstreet:online

Summit Therapeutics (NASDAQ:SMMT) Trading 3.6% Higher - MarketBeat

Summit Therapeutics Inc (SMMT)'s stock rises to 3.88 per share – US Post News - US Post News

Summit Therapeutics Inc (SMMT)'s stock rises to 3.88 per share – US Post News - US Post News

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 - Business Wire

Wall Street Breakfast: The Week Ahead

Summit Therapeutics Appoints Biotech Veteran to Board - TipRanks.com - TipRanks

Summit Therapeutics appoints genomics expert to board By Investing.com - Investing.com

Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor - WTAQ

Summit Therapeutics Announces Major Leadership Restructuring - TipRanks.com - TipRanks

Summit Therapeutics CFO Ankur Dhingra steps down By Investing.com - Investing.com

Why Summit Therapeutics Stock Crushed the Market This Week

Why Summit Therapeutics Stock Crushed the Market This Week - Yahoo Finance

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Summit Therapeutics CEO acquires shares worth over $411k - Investing.com

Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment

Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday

Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment - Markets Insider

Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment - Yahoo Finance

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In ... - Markets Insider

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Summit Therapeutics Showcases at Barclays Healthcare Conference - TipRanks.com - TipRanks

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc ... - PR Newswire

SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors - TipRanks.com - TipRanks

Simile a SMMT